The following criteria is provided for health care professionals.

Inclusion Criteria:

• Subjects must have a confirmed prior diagnosis of active MM as defined by the IMWG criteria 20.
• Subjects must have relapsed or refractory disease after either one of the following:
  • At least 3 prior regimens, which must have contained an alkylating agent, proteasome inhibitor, and immunomodulatory agent (IMiD). OR
  • At least 2 prior regimens if "double-refractory" to a proteasome inhibitor and IMiD, defined as progression on or within 60 days of treatment with these agents.
  • Note: induction therapy, stem cell transplant, and maintenance therapy, if given sequentially without intervening progression, should be considered as 1 "regimen".
• Subjects must have signed written, informed consent.
• Subjects must be ≥ 18 years of age.
• Subjects must be at least 90 days since autologous stem cell transplant, if performed.
• Subjects must have adequate vital organ function:
  1. Serum creatinine ≤ 2.5 or estimated creatinine clearance ≥30 ml/min and not dialysis-dependent.
  2. Absolute neutrophil count ≥1000/μl and platelet count ≥50,000/μl (≥30,000/μl if bone marrow plasma cells are ≥50% of cellularity).
  3. SGOT ≤ 3x the upper limit of normal and total bilirubin ≤ 2.0 mg/dl (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome).
  4. Left ventricular ejection fraction (LVEF) ≥ 45%. LVEF assessment must have been performed within 8 weeks of enrollment.
  5. Toxicities from prior therapies, with the exception of peripheral neuropathy attributable to bortezomib, must have recovered to grade ≤ 2 according to the CTC 4.0 criteria or to the subject's prior baseline.
• Subjects must have an ECOG performance status of 0-2.

Exclusion Criteria:

• Be pregnant or lactating.
• Have inadequate venous access for or contraindications to leukapheresis.
• Have any active and uncontrolled infection.
• Have active hepatitis B, hepatitis C, or HIV infection.
• Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined.
• Have NYHA Class III or IV heart failure, unstable angina, or a history of recent (within 6 months) myocardial infarction or sustained (>30 seconds) ventricular tachyarrhythmias.
• Have undergone allogeneic stem cell transplantation.
• Have received prior gene therapy or gene-modified cellular immunotherapy. Subject may have received, however, non-gene-modified autologous T-cells in association with an anti-myeloma